ClearPoint Neuro

Ambrx Biopharma (NASDAQ: AMAM) Stock Quote

Follow Insider Trades Visit website
Last Trade: US$14.92 0.39 2.68
Volume: 365,702
5-Day Change: -0.33%
YTD Change: 557.27%
Market Cap: US$824.030M

Latest News From Ambrx Biopharma

May 30, 2023
Ambrx Biopharma to Present at Multiple Upcoming Investor Meetings
SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc. , or Ambrx (or the “Company”) (NASDAQ: AMAM), today announced that Daniel J. O’Connor, Chief Executive Officer and President of Ambrx, will present a corporate overview at the TD Cowen Oncology Innovation Summit, the Jefferies Healthcare Conference, and the Goldman Sachs 44 th Annual Global Healthcare Conference in the coming weeks. The presentations will focus... Read More
May 24, 2023
Ambrx Biopharma Announces $75 Million Market Priced Registered Offering
SAN DIEGO, May 24, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc. , or Ambrx (or the “Company”) (NASDAQ: AMAM), today announced that it has entered into a securities purchase agreement with clients managed by Darwin Global Management Ltd. (“Darwin”) for the sale of an aggregate of approximately 5.4 million American Depositary Shares of the Company (“ADS”) at a price of $13.93 per ADS, which is based on the 5-day trailing VWAP... Read More
May 18, 2023
Ambrx Biopharma Appoints Stephen Glover as Chairman of its Board of Directors
SAN DIEGO, May 18, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc. , or Ambrx (NASDAQ: AMAM), today announced that Stephen Glover has joined the Company’s Board of Directors as Chairman. Mr. Glover has extensive experience building successful biopharmaceutical companies, with a focus on pharmaceutical business strategy, corporate development, product development, commercialization, and business optimization. The Company’s... Read More
May 11, 2023
Ambrx to Present at JMP Securities Life Sciences and RBC Capital Markets Global Healthcare Conferences
SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (NASDAQ: AMAM), today announced that Daniel J. O’Connor, Chief Executive Officer and President of Ambrx, will present a corporate overview at the JMP Securities Life Sciences Conference and RBC Capital Markets Global Healthcare Conference taking place in New York City on May 16 th and 17 th , respectively. The presentations will focus on the status of... Read More
May 4, 2023
Ambrx Biopharma Expands Leadership Team with Appointment of Andrew Aromando as Chief Operating Officer
SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc. , or Ambrx (NASDAQ: AMAM), today announced the appointment of Andrew P. Aromando as Chief Operating Officer. Mr. Aromando brings over 30 years of experience across numerous functional areas in the biopharmaceutical industry, serving in senior executive roles focused on corporate development, clinical operations, and commercial strategy. He will be responsible... Read More
April 19, 2023
Ambrx Presents New Preclinical Data on ARX517 and ARX305 at the 2023 AACR Annual Meeting
SAN DIEGO, April 19, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (NASDAQ: AMAM), announced new preclinical data at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida, held from April 14 to 19, 2023. Ambrx’s presentations highlight data from preclinical studies of ARX517, the only anti-PSMA ADC in clinical development, and ARX305, one of two anti-CD70 ADCs in active... Read More
March 27, 2023
Ambrx Biopharma to Present Preclinical Data on ARX517 and ARX305 at the 2023 AACR Annual Meeting
SAN DIEGO, March 27, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc. , or Ambrx (NASDAQ: AMAM), announced the presentation of three posters featuring preclinical data at the upcoming 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida, from April 14 to 19, 2023. The two preclinical posters will provide data from Ambrx’s preclinical studies of ARX517 (anti-PSMA ADC) and ARX305 (anti-CD70... Read More
March 6, 2023
Ambrx Biopharma to Commence Trading on Nasdaq
SAN DIEGO / Mar 06, 2023 / Business Wire / Ambrx Biopharma Inc. (NYSE: AMAM ) (“Ambrx” or “the Company”) today announced that it will voluntarily transfer its stock exchange listing to the Nasdaq Stock Market from the New York Stock Exchange, effective March 16, 2023 after market close. Ambrx’s American Depositary Shares are expected to begin trading as a Nasdaq-listed security on March 17, 2023. The Company will retain its... Read More
February 16, 2023
ARX517, Ambrx’s Proprietary Anti-PSMA ADC, Shows Encouraging Single-Agent Safety and Efficacy Data in Patients with Advanced Prostate Cancer
SAN DIEGO / Feb 16, 2023 / Business Wire / Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM) today announced encouraging initial data from its ongoing Phase 1 trial (APEX-01 (NCT04662580)) investigating ARX517, Ambrx’s proprietary anti-PSMA ADC, in prostate cancer patients. APEX-01 is a Phase 1, first-in-human, open label dose escalation and dose expansion trial enrolling patients with advanced prostate cancer whose tumors have... Read More
February 13, 2023
Ambrx Biopharma to Host Analyst and Investor Day to Discuss ARX788 in Breast Cancer and ARX517 in Prostate Cancer
Virtual presentation to take place on February 24, 2023 at 12:00pm ET Event will feature discussions regarding ARX788, Ambrx’s proprietary anti-HER2 targeting ADC, from key opinion leaders in breast cancer, Hope S. Rugo, M.D., FASCO, and Paula R. Pohlmann, M.D., M.S., Ph.D. Data update for APEX-01, a first-in-human study evaluating the safety and anti-tumor activity of ARX517, Ambrx’s proprietary anti-PSMA ADC, in prostate... Read More
February 3, 2023
Ambrx Biopharma Strengthens Clinical Leadership with Appointment of Sandra Aung, Ph.D. as Head of Clinical Development
SAN DIEGO / Feb 03, 2023 / Business Wire / Ambrx Biopharma, Inc., or Ambrx (NYSE: AMAM), a clinical stage biopharmaceutical company using its proprietary Engineered Precision Biologics (EPBs) platform to create antibody-drug conjugates (ADCs), has appointed Sandra Aung, Ph.D., as Executive Vice President, Head of Clinical Development. Dr. Aung will assume all clinical development leadership responsibilities of Ambrx’s... Read More
December 9, 2022
Ambrx Biopharma Announces Encouraging Preliminary Safety and Efficacy Data Evaluating ARX788 in HER2 Positive Metastatic Breast Cancer Patients Who Progressed Following T-DM1 Treatment
Data to be discussed in a Spotlight Poster Presentation at the 2022 San Antonio Breast Cancer Symposium Preliminary Phase 2 results from ACE-Breast-03 study demonstrate 57.1% confirmed overall response rate (ORR) by RECIST v1.1 and 100% disease control rate (DCR) in heavily pre-treated patients with HER2 positive metastatic breast cancer (mBC) following treatment with Ambrx’s ARX788 anti-HER2 Antibody Drug Conjugate No... Read More
ClearPoint Neuro

COPYRIGHT ©2023 HEALTH STOCKS HUB